Not independent
Tenure on this board
16.1 yrs
Meeting calendar
MLAB · Annual meeting · Friday, August 22, 2025
Mesa Laboratories Inc
7 nominees · 4 ballot items.
Election of seven director nominees for a one-year term; ratification of Baker Tilly US, LLP as independent auditors for the fiscal year ending March 31, 2026; advisory vote on executive compensation; and approval of an amendment to the 2021 Equity Incentive Plan increasing the share reserve.
Market cap
$577M
1Y TSR
+3.7%
Board grade
D
Record date
Jul 3, 2025
Filing
DEF 14A
Meeting concluded · Aug 22, 2025
Follow how the vote landed and what changed on Mesa Laboratories Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of seven director nominees
ManagementBoard: FORElection of seven director nominees named in the proxy for a term of one year.
- 2
Ratification of the Selection of Baker Tilly US, LLP as Independent Auditors
ManagementBoard: FORRatification of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the fiscal year ending March 31, 2026.
- 3
Advisory Vote to Approve Executive Compensation
ManagementBoard: FORAdvisory, non-binding vote to approve the compensation of the company's named executive officers.
- 4
Approval of an Amendment to the Mesa Laboratories, Inc. 2021 Equity Incentive Plan
ManagementBoard: FORApproval of an amendment to increase the 2021 Equity Incentive Plan share reserve from 660,000 to 1,156,000 shares.
Director elections
Nominees on the ballot7
Not independent
Tenure on this board
8.8 yrs
Independent
Tenure on this board
7.3 yrs
Independent
Tenure on this board
6.1 yrs
Independent
Tenure on this board
4.7 yrs
Independent
Tenure on this board
4.0 yrs
Also a director at
Origin Materials Inc (ORGN)Iperionx Ltd (IPX)
Independent
Tenure on this board
2.5 yrs
Also a director at
Sera Prognostics Inc (SERA)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Long Path Partners LP | 7.3% | 405,583 | $36M |
| 2 | Boston Partners | 4.9% | 268,711 | $24M |
| 3 | Select Equity Group, L.P. | 4.3% | 235,885 | $21M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 232,643 | $21M |
| 5 | Ranger Investment Management, L.P. | 3.7% | 202,903 | $18M |
| 6 | BlackRock, Inc. | 3.4% | 186,969 | $17M |
| 7 | AQR CAPITAL MANAGEMENT LLC | 3.1% | 168,986 | $15M |
| 8 | ROYCE ASSOCIATES LP | 2.9% | 161,229 | $14M |
| 9 | DIAMOND HILL CAPITAL MANAGEMENT INC | 2.8% | 155,302 | $14M |
| 10 | KENNEDY CAPITAL MANAGEMENT LLC | 2.6% | 142,343 | $13M |
Peers
Nearest market capOther Technology sector meetings6
Upcoming shareholder meetings at Mesa Laboratories Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Nve CorpNVEC
Annual meeting·Aug 6, 2026·$506M
Gloo Holdings IncGLOO
Annual meeting·Jul 13, 2026·$374M
Nano Dimension LtdNNDM
Special meeting·Jul 31, 2026·$303M
Gigacloud Technology IncGCT
Annual meeting·Jul 10, 2026·$1.2B
Dxc Technology CoDXC
Annual meeting·Jul 21, 2026·$1.4B
Kyndryl Holdings IncKD
Annual meeting·Jul 30, 2026·$2.5B
Reference
Frequently asked questions
- When is the Mesa Laboratories Inc 2025 annual meeting?
- Mesa Laboratories Inc (MLAB) holds its 2025 annual shareholder meeting on Friday, August 22, 2025.
- What is the record date for the Mesa Laboratories Inc 2025 meeting?
- The record date for the Mesa Laboratories Inc 2025 meeting is Thursday, July 3, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Mesa Laboratories Inc's 2025 meeting?
- The board is presenting 7 director nominees at the Mesa Laboratories Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Mesa Laboratories Inc 2025 meeting?
- Shareholders will vote on 4 proposals at the Mesa Laboratories Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.